Selskabets formål er at drive virksomhed med fremstilling og salg af mikrobiologiske metoder til måling af mikrobiel kontaminering, og dermed beslægtet virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 8.3 mio. | -13.8 mio. | 28.1 mio. | 17.3 mio. | 12 | |
CVR: 24231712
Secondary names: MYCOTEC A/S, Bactimatic A/S
Previous names: MYCOTEC ApS, MYCOMETER ApS, MYCOMETER A/S
Compared to 1.002 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
BactiQuant A/S is currently facing significant financial challenges, with consistent losses over the past five years. In 2025, the company reported a revenue of 8.3 million DKK but incurred a loss of 13.8 million DKK, indicating a concerning trend of declining profitability despite a slight increase in revenue from 2024. Equity has fluctuated, rising to 17.3 million DKK in 2025 from a low of 689,233 DKK in 2024, suggesting some recovery in financial stability. However, the persistent negative profit margins and reliance on external funding raise concerns about its long-term viability within the competitive research and development sector.
AI-generated summary
Mette Juhl Jørgensen left the board
Murugasan Claes Nielsen joined as director
Murugasan Claes Nielsen registered with 5% ownership
Companies in the same industry and area
CVR 39315424
CVR 31261570
CVR 45766470
CVR 33167512
CVR 36051183
companydata.dk